Preparation method of atorvastatin calcium

By using acetonitrile as a reaction solvent in the preparation of atorvastatin calcium and transcrystallization under specific temperature and pH conditions, the problem that the preparation of atorvastatin calcium in the prior art does not meet the pharmaceutical standards, achieving high Preparation of atorvastatin calcium with purity and high yield, suitable for industrial production.

CN118930468APending Publication Date: 2024-11-12SUZHOU DAWNRAYS PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410982245.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing preparation method of atorvastatin calcium is difficult to meet the medicinal standards. The product is non-medical crystal form, the purity does not meet the requirements, and the reaction conditions are relatively high, there are many by-products, and the solubility and clarity are unqualified.

Method used

Acetylene is used as the reaction solvent, acid hydrolysis and alkali hydrolysis are carried out at 20-30°C, and the pH value is adjusted. Then, the crystallization and cultivation are carried out through a system of methanol, acetonitrile, and alkaline substances to obtain the original medicinal crystal form I crystal form atorvastatin calcium.

Benefits of technology

The preparation index of atorvastatin calcium has been achieved to meet the medicinal standards, the reaction process is fast, the by-products are few, the product is high, the solubility and clarity are qualified, and it is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930468A_ABST
    Figure CN118930468A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of atorvastatin calcium, which comprises the following steps: (1) adding acetonitrile, atorvastatin condensate, water and monoacid into a reaction container, and reacting at 20-30 DEG C; (2) adding monobasic alkali into the reaction liquid in the step (1) to adjust the pH value of the reaction system to 12-13, reacting at 20-30 DEG C, and after the reaction is finished, adding an acidic material to adjust the pH value to 9-11; (3) distilling the reaction solution obtained in the step (2), adding a mixed solution of methanol, water and other organic solvents for extraction, washing the water phase with other organic solvents to remove impurities, and adding a calcium salt for reaction to obtain an atorvastatin calcium crude product; and (4) performing crystal transformation on the atorvastatin calcium crude product in the step (3) in a mixed system of methanol, acetonitrile, an alkaline substance and water at 40-60 DEG C, and performing crystallization and crystal growing at 0-8 DEG C. The method is mild in reaction condition, simple to operate, high in product purity, high in yield, low in cost and suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to a method for preparing atorvastatin calcium. Background Art

[0002] Atorvastatin calcium is a statin lipid-regulating drug. Its main site of action is the liver. It can reduce the synthesis of cholesterol, increase the synthesis of low-density lipoprotein receptors, reduce the levels of total cholesterol, low-density lipoprotein and triglycerides, moderately reduce serum triglyceride levels and increase blood high-density lipoprotein levels.

[0003] The chemical name of atorvastatin calcium is (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanoate calcium trihydrate, and the structural formula is as follows:

[0004]

[0005] Atorvastatin calcium is prepared by deprotection, hydrolysis and salt formation of the key intermediate condensation product. The structural formula of the key intermediate condensation product is as follows:

[0006]

[0007] Although the prior art provides a variety of methods for preparing atorvastatin calcium, the prepared products are difficult to meet the pharmaceutical standards for raw materials. For example, patent CN102344401A uses methanol and tetrahydrofuran as solvents, acid deprotection and alkaline hydrolysis reactions are carried out continuously, the calcium salt is extracted with propyl acetate, butyl acetate or ethyl acetate, and then acetone is added to dissolve and concentrate to obtain amorphous atorvastatin calcium, which is a non-pharmaceutical crystal form and the purity does not meet the pharmaceutical standards. Patent CN102796036A uses tetrahydrofuran as solvent, first alkaline hydrolysis and then acid hydrolysis, ethyl acetate, cyclohexane and diatomaceous earth are used for impurity removal, sodium salt is prepared first and then calcium salt is prepared, and the product is a non-pharmaceutical crystal form. Patent CN101560177A uses C 1 -C 10 Organic acid, tartaric acid, oxalic acid, benzoic acid, salicylic acid and any two mixtures thereof are deprotected, hydrolyzed in an alcohol solvent system such as ethanol, methanol, isopropanol, n-butanol or a mixed solvent thereof, and reacted with calcium chloride or calcium nitrate to obtain crude atorvastatin calcium, the acid hydrolysis temperature of which is 50°C, and the lactone impurity content is high. Patent CN105085362A uses ethanol, methanol, and isopropanol as solvents, acid hydrolysis, alkaline hydrolysis, methyl tert-butyl ether to remove impurities, and forms calcium salts. The amount of solvent used is large, the acid hydrolysis and alkaline hydrolysis temperatures are high, the acid hydrolysis and alkaline hydrolysis by-products are large and difficult to remove, the product solubility and clarity are difficult to meet the standards for raw material pharmaceuticals.

[0008] Therefore, developing a preparation method for atorvastatin calcium that meets pharmaceutical standards is the focus of research on atorvastatin calcium raw materials. Summary of the invention

[0009] The purpose of the present invention is to provide a method for preparing atorvastatin calcium. All indicators of the atorvastatin calcium prepared by the method meet the pharmaceutical standards, and the reaction process is fast and the product yield is high.

[0010] In order to achieve the above object, the technical solution adopted by the present invention is:

[0011] A method for preparing atorvastatin calcium, characterized in that the preparation method comprises the following steps:

[0012] (1) adding acetonitrile, atorvastatin condensate, water and monobasic acid into a reaction vessel and reacting at 20 to 30° C.;

[0013] (2) adding a monobasic base to the reaction solution of step (1) to adjust the pH value of the reaction system to 12-13, reacting at 20-30° C., and after the reaction is completed, adding an acidic substance to adjust the pH value of the reaction system to 9-11;

[0014] (3) first distilling the reaction solution of step (2), then adding methanol, water and other organic solvent mixture for extraction, washing the aqueous phase with other organic solvents to remove impurities, and then adding calcium acetate to obtain crude atorvastatin calcium, wherein the other organic solvent is one or more of dichloromethane, cyclohexane and methyl tert-butyl ether;

[0015] (4) the crude atorvastatin calcium of step (3) is crystallized in a mixed system of methanol, acetonitrile, alkaline substance and water at 40-60° C., crystallized at 0-8° C. and grown to obtain the atorvastatin calcium.

[0016] The structural formula of the atorvastatin condensate is:

[0017]

[0018] The crystal form of atorvastatin calcium after crystal transformation is the original pharmaceutical crystal form I.

[0019] Preferably, the monoacid in step (1) is one or more of hydrochloric acid, sulfuric acid, formic acid, acetic acid or p-toluenesulfonic acid.

[0020] Preferably, the monobasic base in step (2) is one or more of sodium hydroxide, potassium hydroxide, sodium bicarbonate or sodium carbonate.

[0021] Preferably, the acidic substance in step (2) is one or more of glacial acetic acid, formic acid, citric acid or citric acid.

[0022] Preferably, the calcium salt in step (3) is one or more of calcium acetate, calcium chloride or calcium formate.

[0023] Preferably, the alkaline substance in step (4) is one or more of sodium hydroxide, potassium hydroxide, sodium bicarbonate or sodium carbonate.

[0024] According to some embodiments, the monoacid in step (1) is hydrochloric acid, the monoacid in step (2) is sodium hydroxide, the acidic substance in step (2) is glacial acetic acid, and the alkaline substance in step (4) is sodium hydroxide.

[0025] Preferably, in step (1), the ratio of acetonitrile to atorvastatin condensate is (2.0-8.0) ml / g.

[0026] Further preferably, in the step (1), the ratio of acetonitrile to atorvastatin condensate is (4.0-6.0) ml / g.

[0027] Preferably, in step (1), the ratio of water to atorvastatin condensate is (0.8-1.5) ml / g.

[0028] Further preferably, in the step (1), the ratio of water to atorvastatin condensate is (0.9-1.2) ml / g.

[0029] Preferably, in step (1), the ratio of the molar amount of the monoacid to the molar amount of the atorvastatin condensate is (0.7-1.3):1.

[0030] Further preferably, in the step (1), the ratio of the molar amount of the monoacid to the molar amount of the atorvastatin condensate is (0.9-1.1):1.

[0031] According to a specific embodiment, the monoacid in step (1) is hydrochloric acid, which is fed in the form of a hydrochloric acid aqueous solution with a mass concentration of 36%.

[0032] Preferably, in the step (2), the ratio of the molar amount of the monobasic base to the molar amount of the atorvastatin condensate is (1.8-2.2):1.

[0033] Further preferably, in the step (2), the ratio of the molar amount of the monobasic base to the molar amount of the atorvastatin condensate is (2.0-2.2):1.

[0034] Preferably, the reaction time of step (1) is 3 to 6 hours.

[0035] More preferably, the reaction time of step (1) is 3 to 5 hours.

[0036] Preferably, the reaction time of step (2) is 0.5 to 2 hours.

[0037] More preferably, the reaction time of step (2) is 1 to 1.5 hours.

[0038] Preferably, in the step (3), the volume ratio of methanol, water and other organic solvents in the mixed solution of methanol, water and other organic solvents is 1:(2.5-3.5):(1.5-2.5).

[0039] Preferably, the ratio of the mixed solution of methanol, water and other organic solvents in step (3) to the atorvastatin condensate in step (1) is (10-15) ml / g.

[0040] Preferably, the ratio of the molar amount of the calcium salt in step (3) to the molar amount of the atorvastatin condensate in step (1) is (0.4-0.8):1.

[0041] Further preferably, the ratio of the molar amount of the calcium salt in step (3) to the molar amount of the atorvastatin condensate in step (1) is (0.5-0.6):1.

[0042] Preferably, in step (3), the calcium salt is added dropwise in the form of a calcium salt aqueous solution, and the salt-forming reaction is stirred while the addition is being added dropwise. The reaction time of the salt-forming reaction is 4 to 24 hours.

[0043] More preferably, the reaction time of the salt-forming reaction is 8 to 24 hours.

[0044] According to some specific embodiments, the step (3) is specifically: distilling the reaction solution of step (2) under reduced pressure, adding methanol, water and other organic solutions to mix, layering, washing the aqueous phase with other organic solutions, removing other organic solutions dissolved in the aqueous phase by distillation under reduced pressure at 20-30°C, adding calcium salt aqueous solution dropwise, continuing stirring for 8-15 hours, filtering, rinsing the filter cake with water, and vacuum drying the wet product at 40-50°C to constant weight.

[0045] Preferably, in step (4), the crystal transformation time is 8 to 24 hours.

[0046] Preferably, in step (4), the crystal growing time is 10 to 15 hours.

[0047] Preferably, the ratio of methanol in step (4) to the atorvastatin condensate in step (1) is (2.0-6.0) ml / g, the ratio of acetonitrile in step (4) to the atorvastatin condensate in step (1) is 1.0-3.0 ml / g, the ratio of water in step (4) to the atorvastatin condensate in step (1) is 10.0-30.0 ml / g, and the alkaline substance in step (4) is sodium hydroxide and the ratio of the molar amount of sodium hydroxide to the molar amount of atorvastatin condensate in step (1) is (0.03-0.3):1.

[0048] According to some specific embodiments, the step (4) is specifically as follows: firstly dissolving the crude atorvastatin calcium of the step (3) in a mixed solution of methanol, acetonitrile, sodium hydroxide and water, then dropping it into water at 40-60°C, crystallizing at 40-60°C for 1-5 hours, controlling the system to cool to 0-8°C over 3-5 hours, keeping the temperature at 0-8°C for 10-15 hours, filtering, washing the filter cake with water, and drying the wet product at 40-50°C to constant weight to obtain the atorvastatin calcium.

[0049] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art:

[0050] The present invention selects acetonitrile as the reaction solvent for the acid hydrolysis and alkaline hydrolysis reactions of atorvastatin condensates, so that the reaction temperature is milder, the reaction progress is fast and the by-product content is small, thereby improving the reaction efficiency and the yield of atorvastatin calcium; atorvastatin calcium is crystallized by a system consisting of methanol, acetonitrile and alkaline water to obtain a target crystal form (original pharmaceutical crystal form I crystal form) with medicinal value, thereby solving the problem that the product prepared by the existing method has unqualified solubility and clarity in methanol; all indicators of the atorvastatin calcium prepared by the method of the present invention meet the pharmaceutical standards. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 is the HPLC spectrum of the crude atorvastatin calcium of Example 1;

[0052] Figure 2 is the HPLC spectrum of the atorvastatin calcium finished product of Example 1;

[0053] Figure 3 is the system suitability HPLC profile of Example 1;

[0054] Figure 4 It is the blank HPLC spectrum of Example 1.

[0055] Figure 5 is the PXRD pattern of the atorvastatin calcium finished product of Example 1;

[0056] Figure 6 This is the HPLC spectrum of the atorvastatin calcium finished product of Comparative Example 1;

[0057] Figure 7 This is the HPLC spectrum of the atorvastatin calcium finished product of Comparative Example 3;

[0058] Figure 8 This is the HPLC spectrum of the system suitability of Comparative Example 3. DETAILED DESCRIPTION

[0059] The existing preparation method of atorvastatin calcium requires acid hydrolysis and alkaline hydrolysis at a relatively high temperature, the by-product content is relatively large, and the solubility and clarity of the prepared product in methanol are unqualified. To this end, the inventors of the present application have conducted a large number of studies and experimental verifications, and unexpectedly found that using acetonitrile as a reaction solvent for acid hydrolysis and alkaline hydrolysis can improve the reaction process and reduce the by-product content under mild conditions of 20 to 30°C, and then the crude atorvastatin calcium is crystallized at a temperature of 40 to 60°C by a system composed of methanol, acetonitrile and alkaline water, and crystallized at a temperature of 0 to 8°C to obtain the target crystal form (original pharmaceutical crystal form I crystal form) that meets the requirements of the pharmacopoeia, and then the following preparation method is proposed:

[0060] (1) adding acetonitrile, atorvastatin condensate, water and monobasic acid into a reaction vessel and reacting at 20 to 30° C.;

[0061] (2) adding a monobasic base to the reaction solution of step (1) to adjust the pH value of the reaction system to 12-13, reacting at 20-30° C., and after the reaction is completed, adding an acidic substance to adjust the pH value of the reaction system to 9-11;

[0062] (3) first distilling the reaction solution of step (2), then adding a mixture of methanol, water and dichloromethane for extraction, washing the aqueous phase with dichloromethane to remove impurities, and then adding calcium acetate to obtain a crude product of atorvastatin calcium;

[0063] (4) The crude atorvastatin calcium of step (3) is crystallized in a mixed system of methanol, acetonitrile, alkaline substance and water at 40-60° C., crystallized at 0-8° C. and grown to obtain the atorvastatin calcium.

[0064] The invention has mild reaction conditions, simple operation, high product purity, high yield, low cost and is suitable for industrial production.

[0065] The present invention is further described below in conjunction with the examples. However, the present invention is not limited to the following examples. The implementation conditions used in the examples can be further adjusted according to the different requirements of specific use, and the implementation conditions not specified are conventional conditions in the industry. The technical features involved in each embodiment of the present invention can be combined with each other as long as they do not conflict with each other.

[0066] In the following examples and comparative examples, the atorvastatin condensate is a homemade product with the structural formula:

[0067] The purity is greater than 99%.

[0068] In the following examples and comparative examples, unless otherwise specified, "%" refers to mass percentage. The atorvastatin condensate was prepared by Suzhou Dawnray Pharmaceutical Co., Ltd. with a purity of 99.68%.

[0069] The original pharmaceutical crystal form is Form I. The Chinese Pharmacopoeia stipulates that atorvastatin calcium is easily soluble in methanol and the solution is clear and colorless.

[0070] The HPLC detection in the following examples and comparative examples was determined by high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Four General Rules 0512), chromatographic column ZORBAXRX-C8, 4.6 mm × 250 mm, 1.8 μm, acetate buffer-acetonitrile-tetrahydrofuran (70:20:10) as mobile phase A, acetate buffer-acetonitrile-tetrahydrofuran (30:60:10) as mobile phase B, detection wavelength of 210 nm, column temperature of 30 ° C, flow rate of 1.0 ml / min.

[0071] Example 1

[0072] Add 200 ml of acetonitrile (4.0 V / W), 50.0 g of atorvastatin condensate (0.076 mol, 1 eq), 50 ml of purified water (1.0 V / W), and 7.8 g of 36% hydrochloric acid (0.076 mol, 1.0 eq) to the reaction bottle, and stir and react at 25°C for 4 hours. Add a solution prepared by 6.0 g of sodium hydroxide (0.15 mol, 2.0 eq) and 10 ml (0.2 V / W) of purified water, and stir and react at 25°C for 1 hour. Use 1.0 g (0.02 W / W) of glacial acetic acid to adjust the pH of the system to 10. Distill under reduced pressure until a large amount of material precipitates, add 100 ml of methanol (2.0 V / W), 300 ml (6.0 V / W) of purified water, and 200 ml (4.0 V / W) of dichloromethane to the reaction bottle, stir for 0.5 hours, and let stand to separate the water layer. The aqueous layer was washed with 100 ml (1.0 V / W) of dichloromethane, and the temperature was controlled at 25°C for 1 hour under reduced pressure distillation. A solution prepared by 7.0 g of calcium acetate (0.044 mol, 0.58 eq) and 70 ml (1.4 V / W) of purified water was added dropwise, and the reaction was continued with stirring for 12 hours. Filter, and the filter cake was rinsed with 400 ml (8.0 V / W) of purified water. The wet product was dried under vacuum at 45°C to constant weight to obtain 45.1 g of crude atorvastatin calcium, with a yield of 97.7% and a HPLC purity of 99.73% ( Figure 1 ). The crude product was not easily soluble in methanol, the solution was not clear, and did not meet the pharmaceutical standards.

[0073] Under stirring, add 200 ml of methanol (4.0 V / W), 100 ml (2.0 V / W) of acetonitrile, 5.0 g (0.1 W / W) of sodium hydroxide and 100 ml (2.0 V / W) of purified water to the reaction bottle, and 45.0 g (0.9 W / W) of crude atorvastatin calcium. After stirring and dissolving at 25 ° C, add dropwise into 1000 ml (20.0 V / W) of 50 ° C purified water (dropping time is 2 h), keep warm at 50 ° C for 1 hour to transform the crystal, slowly cool to 5 ° C (about 4 hours to 5 ° C), keep warm at 5 ° C for 12 hours to grow the crystal. Filter, and wash the filter cake with 100 ml (2.0 V / W) of purified water. The wet product is dried at 45 ° C to constant weight to obtain 43.1 g of atorvastatin calcium finished product, with a yield of 95.8% and a HPLC purity of 99.78% ( Figure 2 ). It has been verified to be the target crystal form (original pharmaceutical crystal form I) ( Figure 5 The finished product is easily soluble in methanol, the solution is clear, and other indicators (including specific rotation, chloride, calcium, moisture, residual solvent, content, etc.) meet the standards for atorvastatin calcium finished products.

[0074] Example 2

[0075] Add 200ml acetonitrile (4.0V / W), 50.0g atorvastatin condensate (0.076mol, 1eq), 50ml purified water (1.0V / W), 3.5g formic acid (0.076mol, 1.0eq) to the reaction bottle, control the temperature at 25°C and stir to react for 4 hours. Add a solution prepared by 8.4g potassium hydroxide (0.15mol, 2.0eq) and 10ml (0.2V / W) purified water, control the temperature at 25°C and stir to react for 1 hour, and adjust the system pH to 10 with 1.0g (0.02W / W) glacial acetic acid. Distill under reduced pressure until a large amount of material precipitates, add 100ml methanol (2.0V / W), 300ml (6.0V / W) purified water and 200ml (4.0V / W) cyclohexane to the reaction bottle, stir for 0.5 hours, and let stand to separate the water layer. The aqueous layer was washed with 100 ml (1.0 V / W) of cyclohexane, and the temperature was controlled at 25°C for 1 hour under reduced pressure distillation. A solution prepared by 4.9 g of calcium chloride (0.044 mol, 0.58 eq) and 70 ml (1.4 V / W) of purified water was added dropwise, and the reaction was continued with stirring for 12 hours. The filter cake was rinsed with 400 ml (8.0 V / W) of purified water. The wet product was dried under vacuum at 45°C to constant weight to obtain 45.0 g of crude atorvastatin calcium, with a yield of 97.5%.

[0076] Under stirring, add 200ml methanol (4.0V / W), 100ml (2.0V / W) acetonitrile, 5.0g (0.1W / W) sodium hydroxide and 100ml (2.0V / W) purified water to the reaction bottle, and 45.0g (0.9W / W) crude atorvastatin calcium. After stirring and dissolving at 25°C, add dropwise to 1000ml (20.0V / W) 50°C purified water (dropping time is 2h), keep warm at 50°C for 1 hour, slowly cool to 5°C (about 4 hours to 5°C), keep warm at 5°C for 12 hours. Filter, and wash the filter cake with 100ml (2.0V / W) purified water. Dry the wet product at 45°C to constant weight to obtain 43.0g atorvastatin calcium finished product, with a yield of 95.6%. The finished product is easily soluble in methanol and the solution is clear.

[0077] Example 3

[0078] Add 200ml acetonitrile (4.0V / W), 50.0g atorvastatin condensate (0.076mol, 1eq), 50ml purified water (1.0V / W), 13.1g p-toluenesulfonic acid (0.076mol, 1.0eq) to the reaction bottle, control the temperature at 25°C and stir to react for 4 hours. Add a solution prepared by 15.9g sodium carbonate (0.15mol, 2.0eq) and 100ml (2.0V / W) purified water, control the temperature at 25°C and stir to react for 1 hour, and adjust the system pH to 10 with 1.0g (0.02W / W) glacial acetic acid. Distill under reduced pressure until a large amount of material precipitates, add 100ml methanol (2.0V / W), 300ml (6.0V / W) purified water and 200ml (4.0V / W) methyl tert-butyl ether to the reaction bottle, stir for 0.5 hours, and let stand to separate the water layer. The aqueous layer was washed with 100 ml (1.0 V / W) of methyl tert-butyl ether, and the temperature was controlled at 25°C for 1 hour under reduced pressure distillation. A solution prepared by adding 5.7 g of calcium formate (0.044 mol, 0.58 eq) and 70 ml (1.4 V / W) of purified water was added dropwise, and the reaction was continued with stirring for 12 hours. The filter cake was rinsed with 400 ml (8.0 V / W) of purified water. The wet product was dried under vacuum at 45°C to constant weight to obtain 45.0 g of crude atorvastatin calcium, with a yield of 97.5%.

[0079] Under stirring, add 200ml methanol (4.0V / W), 100ml (2.0V / W) acetonitrile, 5.0g (0.1W / W) sodium hydroxide and 100ml (2.0V / W) purified water to the reaction bottle, and 45.0g (0.9W / W) crude atorvastatin calcium. After stirring and dissolving at 25°C, add dropwise to 1000ml (20.0V / W) 50°C purified water (dropping time is 2h), keep warm at 50°C for 1 hour, slowly cool to 5°C (about 4 hours to 5°C), keep warm at 5°C for 12 hours. Filter, and wash the filter cake with 100ml (2.0V / W) purified water. Dry the wet product at 45°C to constant weight to obtain 43.0g atorvastatin calcium finished product, with a yield of 95.6%. The finished product is easily soluble in methanol and the solution is clear.

[0080] Comparative Example 1

[0081] Reference CN105085362A Example 1

[0082] 50g of atorvastatin condensate and 1600ml of ethanol were added to a reaction bottle, heated to an internal temperature of 40°C, 95ml of 2mol / L hydrochloric acid solution was added dropwise, and the acid hydrolysis reaction was carried out for 2h; then 120ml of 2mol / L sodium hydroxide solution was added dropwise, and the alkaline hydrolysis reaction was carried out for 1h, deionized water was added, and the pH was adjusted to 8.0 with 2mol / L hydrochloric acid solution under stirring, 1.5g of activated carbon was added, and the mixture was stirred for 1h, filtered, and the filtrate was extracted twice with methyl tert-butyl ether, the aqueous phase was concentrated, 200ml of water was added, and the mixture was heated to 42°C after filtration, 500ml of 3.2% calcium acetate solution was added dropwise, and then 0.5g of seed crystals was added and stirred for 10h, filtered, and the wet product of atorvastatin calcium was obtained by elution with deionized water, and the finished product of atorvastatin calcium was obtained by air drying at 70°C, with a yield of 90.3% and a purity of 99.17% by HPLC ( Figure 6 ), due to the high hydrolysis temperature, the by-products of acid hydrolysis 0.16%, not in compliance with pharmacopoeia standards, a byproduct of alkaline hydrolysis It is 0.13%, which does not meet the pharmacopoeia standard. The finished product is not easily soluble in methanol, the solution is not clear, and does not meet the pharmaceutical standards.

[0083] Comparative Example 2

[0084] 50g of atorvastatin condensate and 1600ml of ethanol were added to a reaction bottle, the internal temperature was controlled at 25°C, 95ml of 2mol / L hydrochloric acid solution was added dropwise, and the acid hydrolysis reaction was carried out at 25°C for 12 hours. The raw material was still not completely reacted and was abandoned. Ethanol was used as a solvent for acid hydrolysis at 40°C, and the impurities were large. The acid hydrolysis reaction at 25°C was very slow, and the solvent system needed to be optimized.

[0085] Comparative Example 3

[0086] Under stirring, add 315 ml of methanol, 158 ml of acetonitrile, and 45.0 g of crude atorvastatin calcium (the preparation method is the same as the preparation method of crude atorvastatin calcium in Example 1) to the reaction bottle, control the temperature at 25°C, stir and dissolve, add dropwise to 675 ml of 65°C purified water (dropping time is 2 hours), and slowly cool to 25°C (about 3 hours to 25°C). Filter, and wash the filter cake with 100 ml of purified water. The wet product is dried at 45°C to constant weight to obtain 39.1 g of finished atorvastatin calcium, with a yield of 86.9% and a HPLC purity of 99.25% ( Figure 7 ). During the refining process, the pH in the system decreases, resulting in lactone impurities. and other impurities.

[0087] The above detailed description of the present invention is intended to enable persons familiar with the art to understand the contents of the present invention and implement them. It does not limit the protection scope of the present invention. All equivalent changes or modifications made according to the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing atorvastatin calcium, characterized in that: The preparation method comprises the following steps: (1) adding acetonitrile, atorvastatin condensate, water and monobasic acid into a reaction vessel and reacting at 20 to 30° C.; (2) adding a monobasic base to the reaction solution of step (1) to adjust the pH value of the reaction system to 12-13, reacting at 20-30° C., and after the reaction is completed, adding an acidic substance to adjust the pH value of the reaction system to 9-11; (3) first distilling the reaction solution of step (2), then adding methanol, water and other organic solvents for extraction, washing the aqueous phase with other organic solvents to remove impurities, and then adding calcium salt to react to obtain crude atorvastatin calcium, wherein the other organic solvent is one or more of dichloromethane, cyclohexane and methyl tert-butyl ether; (4) the crude atorvastatin calcium of step (3) is crystallized in a mixed system of methanol, acetonitrile, alkaline substance and water at 40-60° C., crystallized at 0-8° C. and grown to obtain the atorvastatin calcium. The structural formula of the atorvastatin condensate is: The crystal form of atorvastatin calcium after crystal transformation is crystal form I as shown in the PXRD pattern of FIG5 .

2. The method for preparing atorvastatin calcium according to claim 1, characterized in that: The monoacid in step (1) is one or more of hydrochloric acid, sulfuric acid, formic acid, acetic acid or p-toluenesulfonic acid; And / or, the monobasic base in step (2) is one or more of sodium hydroxide, potassium hydroxide, sodium bicarbonate or sodium carbonate; And / or, the acidic substance in step (2) is one or more of glacial acetic acid, formic acid, citric acid or citric acid; And / or, the calcium salt in step (3) is one or more of calcium acetate, calcium chloride or calcium formate; And / or, the alkaline substance in step (4) is one or more of sodium hydroxide, potassium hydroxide, sodium bicarbonate or sodium carbonate.

3. The method for preparing atorvastatin calcium according to claim 1, characterized in that: In the step (1), the ratio of acetonitrile to atorvastatin condensate is (2.0-8.0) ml / g; And / or, in the step (1), the ratio of water to atorvastatin condensate is (0.8-1.5) ml / g.

4. The method for preparing atorvastatin calcium according to claim 1, characterized in that: In the step (1), the ratio of the molar amount of the monoacid to the molar amount of the atorvastatin condensate is (0.7-1.3):1; And / or, in the step (2), the ratio of the molar amount of the monobasic base to the molar amount of the atorvastatin condensate is (1.8-2.2):

1.

5. The method for preparing atorvastatin calcium according to claim 1, characterized in that: The reaction time of step (1) is 3 to 6 hours.

6. The method for preparing atorvastatin calcium according to claim 1, characterized in that: The reaction time of step (2) is 0.5 to 2 hours.

7. The method for preparing atorvastatin calcium according to claim 1, characterized in that: In the step (3), the volume ratio of methanol, water and other organic solvents in the mixed solution of methanol, water and other organic solvents is 1:(2.5-3.5):(1.5-2.5); And / or, the ratio of methanol, water and other organic solvents in step (3) to the atorvastatin condensate in step (1) is (10-15) ml / g.

8. The method for preparing atorvastatin calcium according to claim 1, characterized in that: In the step (3), the calcium salt is added dropwise in the form of a calcium salt aqueous solution, and the salt-forming reaction is stirred while the addition is being added dropwise. The reaction time of the salt-forming reaction is 4 to 24 hours.

9. The method for preparing atorvastatin calcium according to claim 1, characterized in that: In the step (4), the crystal conversion time is 1 to 5 hours; and / or, in the step (4), the crystal growing time is 10 to 15 hours.

10. The method for preparing atorvastatin calcium according to claim 1, characterized in that: The ratio of methanol in the step (4) to the atorvastatin condensate in the step (1) is (2.0-6.0) ml / g, the ratio of acetonitrile in the step (4) to the atorvastatin condensate in the step (1) is 1.0-3.0 ml / g, the ratio of water in the step (4) to the atorvastatin condensate in the step (1) is 10.0-30.0 ml / g, and the alkaline substance in the step (4) is sodium hydroxide and the ratio of the molar amount of sodium hydroxide to the molar amount of atorvastatin condensate in the step (1) is (0.03-0.3):1.